Compare Novo Nordisk A/S (NVO) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Star Bulk Carriers Corp — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Star Bulk Carriers Corp trades at $29.7 (market cap $3.54B). The key difference: Novo Nordisk A/S is far larger — about 46.7× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (6.17%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Star Bulk Carriers Corp for 24 Days on average.
| NVO | SBLK | |
|---|---|---|
Market Cap | $165.31B | $3.54B |
Volume | 11,432,838 | 1,437,622 |
Sector | Health | Industrials |
52-Week High | $63.98 | $32.49 |
52-Week Low | $35.29 | $16.79 |
Typical Hold Time | 116 Days | 24 Days |
Enterprise Value | $179.56B | $4.22B |
Dividend Yield | 4.71% | 6.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Star Bulk Carriers (SBLK) trades at $30.47, up 2.63% today, with a bullish technical signal from moving averages and consistent earnings beats in recent quarters. The company reported strong Q2 2026 EPS of $1.21, exceeding expectations, and maintains a 100% free cash flow distribution policy, highlighted by a $0.90 dividend for H2 2026. Valuation metrics show a P/E of 11.95 and EV/EBITDA of 8.34, indicating reasonable pricing relative to earnings.
The outlook remains positive due to robust earnings growth, shareholder returns, and insider buying, but risks include shipping market volatility and reliance on global trade cycles. Analyst consensus is bullish with 14 buy ratings, supporting potential upside if operational momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
